Cost Effectiveness and Resource Allocation

Fig. 3 | Cost Effectiveness and Resource Allocation

Fig. 3

From: Cost-utility analysis of certolizumab pegol versus alternative tumour necrosis factor inhibitors available for the treatment of moderate-to-severe active rheumatoid arthritis in Spain

Fig. 3

ISSN: 1478-7547

Contact us

General enquiries: journalsubmissions@springernature.com